Business Context and Reporting Period
This Form 8-K, filed on July 15, 2026, reports on events occurring on July 9 and July 14, 2026, for Glucotrack, Inc. (the "Acquiror"). The filing details the completion of a reverse merger with Lokahi Therapeutics, Inc. (the "Company"), the execution of a Bridge Financing, and the establishment of an Equity Line of Credit (ELOC). As a result of the merger, Lokahi Therapeutics became a wholly-owned subsidiary of Glucotrack, and Glucotrack's existing business was transferred to a subsidiary, Glucotrack Technologies Inc. ("Operating Sub").
Key Financial Metrics and Capital Structure
- Merger Consideration: Existing Lokahi Therapeutics shareholders received Glucotrack Common Stock and Series A Convertible Preferred Stock. Post-transaction, Lokahi shareholders collectively hold approximately 90.0% of the fully diluted equity, while existing Glucotrack shareholders hold a minimum of 10.0% (the "Acquiror Stockholder Floor").
- Bridge Financing: Glucotrack raised approximately $4.45 million in gross proceeds via senior secured convertible promissory notes and warrants. The notes carry an 8% annual interest rate, a 22% original issue discount, and mature in nine months.
- Equity Line of Credit (ELOC): Glucotrack entered into an agreement with White Lion Capital LLC to purchase up to $50 million of common stock over three years. As consideration, Glucotrack issued commitment shares valued at $1 million and a warrant to purchase up to $10 million of stock.
- Subsidiary Contribution: An aggregate of $7 million is to be deposited into an account for the Operating Sub in installments, contingent on specific milestones such as Nasdaq listing compliance and stock price performance.
- Debt Assumption: Lokahi Therapeutics assumed all obligations of Glucotrack under a promissory note dated September 12, 2025.
- Liquidity: The filing states the Acquiror believes it has stockholders' equity in excess of the $2.5 million requirement for Nasdaq Capital Market listing, pending formal determination.
Material Changes Versus Prior Period
- Corporate Structure: The company underwent a reverse merger, changing the surviving entity's operational focus and ownership structure. Lokahi Therapeutics is now the primary operating entity within the Glucotrack corporate family.
- Management Changes: Paul V. Goode resigned as CEO. Erik Emerson was appointed as the new Chief Executive Officer and a member of the Board of Directors.
- Capitalization: Significant dilution occurred for existing Glucotrack shareholders, who are now capped at a 10% floor of the fully diluted equity. New debt and warrant obligations were created through the Bridge Financing and ELOC.
- Asset Transfer: Glucotrack's existing business assets, including intellectual property for the Glucotrack Continuous Blood Glucose Monitor, employees, and cash, were transferred to the Operating Sub.
Guidance, Outlook, and Risks
- Stockholder Approvals: The transaction requires stockholder approval for the issuance of shares exceeding 19.99% of outstanding common stock (Nasdaq Rule 5635). A proxy statement is to be filed, and a stockholder meeting must be held promptly.
- Conversion Conditions: The Series A Preferred Stock will automatically convert to common stock within five business days after obtaining stockholder approval and Nasdaq listing approval. A "Conversion Deadline" of 90 days (extendable by 60 days) applies.
- Financing Risks: The Bridge Financing includes "Most Favored Nations" provisions and penalties for delayed registration filings or stockholder approvals. The ELOC includes liquidated damages for failure to file registration statements or obtain stockholder approval within specified timeframes.
- Operational Risks: Risks include the failure to integrate businesses, inability to secure additional financing (including a planned $30 million Private Placement Offering), and potential delisting if Nasdaq requirements are not met.
- Forward-Looking Statements: Management anticipates the transactions will provide capital for operations but warns that actual results may differ due to integration challenges, market conditions, and regulatory hurdles.
Investor Verification Checklist
- Verify the filing and effectiveness of the Proxy Statement (Schedule 14A) and the outcome of the required stockholder vote.
- Confirm Nasdaq's formal determination regarding compliance with the $2.5 million stockholders' equity requirement.
- Monitor the status of the $30 million Private Placement Offering and the initial $10 million closing requirement.
- Review the terms of the Bridge Financing notes, specifically the conversion price floor and the 22% original issue discount impact on future dilution.
- Check for the filing of the Form S-3 (or S-1) registration statement required for the resale of merger consideration and ELOC shares.
- Assess the financial statements of Lokahi Therapeutics, which are required to be filed as an amendment to this 8-K within 71 days.